Back to Journals » OncoTargets and Therapy » Volume 10

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma

Authors Li J, Wang L

Received 19 January 2017

Accepted for publication 14 June 2017

Published 7 August 2017 Volume 2017:10 Pages 3965—3969

DOI https://doi.org/10.2147/OTT.S132756

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Jianqiang Li,1 Lifen Wang2

1Department of Thoracic Oncological Surgery, 2Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China

Objective: No standard chemotherapy is available for patients with advanced esophageal squamous cell carcinoma (ESCC) who have failed prior first-line chemotherapy. The aim of this study was to evaluate the efficacy and safety of apatinib, an oral VEGFR-2 inhibitor, as salvage treatment for advanced ESCC.
Patients and methods: After apatinib dosing, the efficacy and toxicity were evaluated in 62 patients with pretreated advanced ESCC from 2014 to 2016 at Zhejiang Cancer Hospital. In addition, survival analysis was performed by the Kaplan–Meier method.
Results: Among the 62 patients, 15 achieved partial response while 31 had stable disease with a response rate of 24.2% and a disease control rate of 74.2%. Median progression-free survival (PFS) and overall survival were 115 and 209 days, respectively. Grade 3/4 toxicities (59.7%) were acceptable. Patients with grade 3/4 toxicities showed a longer PFS than those without (136 vs 63 days, P=0.044).
Conclusion: Apatinib is efficacious as second- or further-line treatment for advanced ESCC.

Keywords: esophageal squamous cell carcinoma, apatinib, vascular endothelial growth factor, toxicity
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]